Lars Bastholt

TL;DR: Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipILimumab alone, and in patients with PD-L1-negative tumors, the combination of PD-1 and CTLA-4 blockade was more effective than either agent alone.

TL;DR: Among patients with advanced melanoma, sustained long-term overall survival at 5 years was observed in a greater percentage of patients who received nivolumab plus ipilimumab or nivoliumab alone than in those who received ipil optimumab alone, with no apparent loss of quality of life in the patients whoreceived regimens containing nivolinumab.

TL;DR: It is suggested that sorafenib is a new treatment option for patients with progressive radioactive iodine-refractory differentiated thyroid cancer and progression-free survival significantly improved in all prespecified clinical and genetic biomarker subgroups, irrespective of mutation status.

TL;DR: As adjuvant therapy for high-risk stage III melanoma, ipilimumab at a dose of 10 mg per kilogram resulted in significantly higher rates of recurrence- free survival, overall survival, and distant metastasis-free survival than placebo.

TL;DR: It is found that the co-occurrence of tumour-associated CD8 + T cells and CD20 + B cells, and the formation of tertiary lymphoid structures, are linked with improved survival in cohorts of patients with metastatic melanoma.